NEW YORK (360Dx) – Oxford Immunotec reported Tuesday that its third quarter revenues increased 17 percent year over year, driven by continued growth in both its tuberculosis and tick-borne disease testing businesses.

For the three months ended Sept. 30, Oxford Immunotec reported total revenues of $30.4 million, up from $26.1 million a year ago, and beating analysts' average estimate of $30.1 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.